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PREFERENCES FOR TREATMENT OUTCOMES IN 
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Congestive heart failure (CHF) affects nearly 5 million
Americans with over 400,000 new cases diagnosed annu-
ally. Total annual costs of care for CHF are estimated be-
tween $20–$40 billion. The CHF syndrome is character-
ized by functional limitations and poor Quality of Life
(QOL). Therapeutic options are thought to include the
ability to either extend life or improve QOL. The balance
of QOL versus survival issues among CHF patients is of
critical importance in prescribing appropriate therapy.
OBJECTIVE: The purpose of this study was to compare
CHF and healthy patients on their preferences for ther-
apy outcomes, evaluating their desire for improved qual-
ity of life versus survival. METHODS: Fifty-one CHF pa-
tients and 47 control subjects (matched for age, gender,
and race) were studied using full-profile conjoint analysis
to determine preferences for treatment outcomes. Sub-
jects rated 16 treatment outcome profiles, consisting of 4
attributes (tiredness, shortness of breath, depression, and
survival) varied across 4 severity levels. Part-worths (util-
ities) and importance weights were calculated for each at-
tribute to determine their relative contribution to the rat-
ing decision using standard conjoint analysis techniques.
RESULTS: Part-worths and importance weights were sig-
nificantly different for shortness of breath and depression
between patients and control subjects. Symptom-sensitive
(n  33) and survival-sensitive (n  17) treatment out-
come preference segments were identified within the
CHF patient group. Importance weights for symptom-
sensitive vs. survival-sensitive patients were: tiredness
0.30  0.10 vs. 0.16  0.09 (P  0.01); shortness of
breath 0.26  0.08 vs. 0.21  0.08 (P  0.07); depres-
sion 0.26  0.09 vs. 0.19  0.09 (P  0.01); and sur-
vival 0.18  0.07 vs. 0.43  0.11 (P  0.01). There were
no significant demographic predictors of which treatment
outcome preference segment a patient belonged. Control
subjects did not display preference segmentation. CON-
CLUSIONS: In this study, CHF patients were found to
be clustered into two subgroups: symptom-sensitive ver-
sus survival-sensitive in a manner suggesting that treat-
ment outcomes of improved symptoms were more impor-
tant to some patients than longer survival. A full
understanding of these individual preferences has impor-
tant implications for the prescribing of therapy for pa-
tients.
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SYSTEMATIC REVIEW EVIDENCE ON TREATING 
HYPERTENSION IN OLDER ADULTS
McDonagh M, Bradley M, Shirley A, Kleijnen J
NHS Centre for Reviews and Dissemination, University of 
York, York, UK
Hypertension is very common, occurring in over 50% of
older people, and is a major risk factor for death from
stroke, congestive heart failure and coronary heart dis-
ease. Antihypertensive drug therapy is the mainstay of
treatment for hypertension. OBJECTIVE: The purpose
was to review the existing evidence from systematic re-
views and meta-analyses on the benefits of drug treat-
ment of hypertension in older people and to compare
the quality and results of individual reviews. METH-
ODS: Studies included were systematic reviews of drug
therapy for hypertension in older adults with a sub-
stantial literature search, appropriate inclusion criteria,
validity assessment, details of studies, and appropriate
pooling. The databases searched were Medline, Co-
chrane Library, HealthStar, Embase, and DARE, years
1993–1999. Quality assessment and data extraction
were performed independently by two reviewers. Out-
comes of interest were overall mortality, stroke morbid-
ity and mortality, CHD morbidity and mortality, and
cardiovascular morbidity and mortality. RESULTS: Ten
systematic reviews met inclusion criteria. Antihyperten-
sive drug therapy was associated with significant reduc-
tions in overall mortality, and mortality due to stroke,
coronary heart disease (CHD), and all cardiovascular
causes. To prevent one cerebrovascular event in the over
60s would mean treating 50 patients for five years. The
quality scores for the ten reviews ranged from 2.4 to 6.9
(0 to 7 possible), with the majority of the studies achiev-
ing a score of five or greater. The results of the meta-
analyses showed similar reductions in morbidity and
mortality, with the exception of those analysing individ-
ual drugs or age group. CONCLUSIONS: Treatment of
hypertension in older people reduces cardiovascular mor-
bidity and mortality by approximately 33%. The quality
differences between systematic reviews did not alter the
results.
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OBJECTIVES: To estimate the burden of hypertension to
a Fortune 500 employer and to assess patient adherence
to prescribed medications. METHODS: The prevalence
of hypertension, resources utilized, and direct costs in-
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curred by hypertensive patients in this employer’s popu-
lation were extracted from medical and pharmacy claims
data for the period October 1, 1996 to September 30,
1997. Hypertension medication compliance for each pa-
tient in the same population was calculated based on the
medication possession rate (MPR  number of days sup-
plied for the single longest prescribed anti-hypertensive
drug for the study year/365 days). A patient who had an
MPR of 80% was considered noncompliant while an
MPR of 80% was considered compliant. RESULTS:
The prevalence rate of hypertension in this employer’s
population (12.6%) was higher than the comparative
MedStat population (9.7%). Of these, 31.1% had hyper-
cholesterolemia and 11.2% had ischemic heart disease in
addition to their hypertension. All resource utilization
rates and direct costs of hypertensive patients in this em-
ployer’s population were higher than those of the com-
parative MedStat population. For example, the cardio-
vascular-related utilization rates for outpatient visits,
hospitalizations, and ER visits were 185.8 (MedStat 
171.3), 12.8 (MedStat  3.5), and 3.3 (MedStat  1.5)
per 1000 members per year, respectively. The total direct
cost payment was approximately $4,833 per hyperten-
sion patient per year, again higher than MedStat’s $3,721
per annual patient cost. Of the 4,924 hypertensive pa-
tients included in these analyses 2,379 (48.3%) were
identified as noncompliant and 2,545 (51.7%) were com-
pliant. CONCLUSIONS: These results were presented to
the employer’s senior management to help them priori-
tize their health management initiatives. A hypertension
disease management program has been developed for this
population and will be implemented first quarter of
2000.
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OBJECTIVE: To assess the trends in the economic bur-
den of illness for the treatment of patients with schizo-
phrenia over a three-year period. METHODS: We esti-
mated the annual per patient direct costs of treatment for
schizophrenia during 1995–1997 in a large administra-
tive claims database (LifeLinkTM) representing approxi-
mately 1.6 million covered lives. Diagnosis-related and
other medical expenditures were estimated for patients
with a diagnosis of schizophrenia. The estimated costs of
care included expenditures for hospitalization, hospital
outpatient services, outpatient medications, psychiatric
day/night facilities, nursing home facilities, office visits,
ER visits, laboratory tests, substance abuse treatment,
and other services. All costs are expressed in 1997 dol-
lars. RESULTS: The prevalence rate of schizophrenia in
the database was 3.2 patients per 1,000 eligible members.
The average annual total cost of care, including medica-
tions, for patients with schizophrenia declined by 15 per-
cent between 1995 and 1997, from $14,612 to $12,435.
Annual patient expenditures for outpatient antipsychotic
medications of interest increased by 48 percent from
$994 in 1995 to $1,474 in 1997, and represented 11.9
percent of total costs in 1997. Annual costs incurred for
services directly associated with a diagnosis of schizo-
phrenia, excluding outpatient medications, declined by
$2,564 (38 percent) between 1995 and 1997. The major-
ity of this reduction was accounted for by services associ-
ated with institutional care. CONCLUSIONS: The total
direct costs of care for patients with schizophrenia in this
study declined between 1995–1997. Increases in the costs
incurred for antipsychotic medications were primarily
offset by declines in other diagnosis-related expenditures.
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OBJECTIVE: The economic burden of illness for the
treatment of bipolar disorder is poorly understood. We
estimated the annual per patient cost of care for individu-
als with this diagnosis in a large population and evalu-
ated trends in cost over a three-year period beginning in
1995. METHODS: We examined the direct costs of care
for bipolar disorder in an employer claims database (Life-
LinkTM) representing the health care experience of ap-
proximately 1.6 million covered lives. The estimated
costs of care included expenditures for hospitalization,
hospital outpatient services, outpatient medications, psy-
chiatric day/night facilities, nursing home facilities, office
visits, ER visits, laboratory tests, substance abuse treat-
ment, and other services. Outpatient medication costs
were separately estimated for mood stabilizers and anti-
psychotic therapies of interest and other outpatient medi-
cation costs. All costs were inflation-adjusted to 1997
dollars. RESULTS: The prevalence of bipolar disorder in
the population was 5.5 patients per 1000 eligible mem-
bers. These patients incurred significant annual expendi-
tures, totaling $13,402 in 1995, $11,856 in 1996, and
$11,146 in 1997. These expenditures were comparable
to the costs of treatment for schizophrenia in the same
